Evaluation of Immunoreactivity with Monoclonal Antibody NCRC 11 in Breast Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 1987 Sep 1

PMID 3663477

Citations 13

Authors

I O Ellis

J Bell

J M Todd

M Williams

C Dowle

A R Robins

C W Elston

R W Blamey

R W Baldwin

Affiliations

Soon will be listed here.

Abstract

Immunocytochemical staining with monoclonal antibody NCRC 11 of formalin fixed paraffin embedded tumour tissue has been studied in 444 cases of primary breast cancer with a minimum follow period of 6 years. The relationship between extent of staining, assessed on a four point scale, and patient survival has been confirmed. There are significant relationships between staining and both histological grade and oestrogen receptor status. No association has been shown between staining and lymph node stage or tumour size. Simplification of staining assessment by modification to two staining groups still allows significant separation of patients into prognostic groups and incorporation into an existing prognostic index.

Citing Articles

The Performance of the Nottingham Prognosis Index and the Adjuvant Online Decision Making Tool for Prognosis in Early-stage Breast Cancer Patients.

Rejali M, Tazhibi M, Mokarian F, Gharanjik N, Mokarian R Int J Prev Med. 2015; 6:93.

PMID: 26605014 PMC: 4629295. DOI: 10.4103/2008-7802.166503.

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.

Rakha E, Soria D, Green A, Lemetre C, Powe D, Nolan C Br J Cancer. 2014; 110(7):1688-97.

PMID: 24619074 PMC: 3974073. DOI: 10.1038/bjc.2014.120.

Preoperative assessment of prognostic factors in breast cancer.

Denley H, Pinder S, Elston C, Lee A, Ellis I J Clin Pathol. 2001; 54(1):20-4.

PMID: 11271783 PMC: 1731277. DOI: 10.1136/jcp.54.1.20.

Expression of MUC2 epithelial mucin in breast carcinoma.

Walsh M, McGuckin M, Devine P, Hohn B, Wright R J Clin Pathol. 1993; 46(10):922-5.

PMID: 8227409 PMC: 501619. DOI: 10.1136/jcp.46.10.922.

Response of breast carcinoma to endocrine therapy predicted using immunostained pelleted fine needle aspirates.

Heyderman E, Ebbs S, Larkin S, Brown B, HAINES A, Bates T Br J Cancer. 1989; 60(4):630-3.

PMID: 2803937 PMC: 2247119. DOI: 10.1038/bjc.1989.328.

References

Maynard P, Blamey R, Elston C, Haybittle J, Griffiths K . Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 1978; 38(11 Pt 2):4292-5. View

Hsu S, RAINE L, FANGER H . Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-80. DOI: 10.1177/29.4.6166661. View

Haybittle J, Blamey R, Elston C, Johnson J, DOYLE P, Campbell F . A prognostic index in primary breast cancer. Br J Cancer. 1982; 45(3):361-6. PMC: 2010939. DOI: 10.1038/bjc.1982.62. View

Holgate C, Jackson P, Cowen P, Bird C . Immunogold-silver staining: new method of immunostaining with enhanced sensitivity. J Histochem Cytochem. 1983; 31(7):938-44. DOI: 10.1177/31.7.6189883. View

Wilkinson M, Howell A, Harris M, Taylor-Papadimitriou J, Swindell R, SELLWOOD R . The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer. 1984; 33(3):299-304. DOI: 10.1002/ijc.2910330304. View

Elston C . The assessment of histological differentiation in breast cancer. Aust N Z J Surg. 1984; 54(1):11-5. DOI: 10.1111/j.1445-2197.1984.tb06677.x. View

BLOOM H, Richardson W . Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957; 11(3):359-77. PMC: 2073885. DOI: 10.1038/bjc.1957.43. View

Berry N, Jones D, Smallwood J, Taylor I, Kirkham N, Taylor-Papadimitriou J . The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer. 1985; 51(2):179-86. PMC: 1977039. DOI: 10.1038/bjc.1985.27. View

Rasmussen B, Pedersen B, Thorpe S, Hilkens J, Hilgers J, Rose C . Prognostic value of surface antigens in primary human breast carcinomas, detected by monoclonal antibodies. Cancer Res. 1985; 45(3):1424-7. View

10.

Ellis I, Hinton C, MacNay J, Elston C, Robins A, Owainati A . Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator. Br Med J (Clin Res Ed). 1985; 290(6472):881-3. PMC: 1417698. DOI: 10.1136/bmj.290.6472.881. View

11.

Price M, Edwards S, Robins R, Hilgers J, Hilkens J, Baldwin R . Epitopes with diagnostic and prognostic significance co-expressed on a human breast carcinoma-associated antigen. Eur J Cancer Clin Oncol. 1986; 22(1):115-7. DOI: 10.1016/0277-5379(86)90351-2. View

12.

Hilkens J, Kroezen V, Bonfrer J, Bruning P . MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res. 1986; 46(5):2582-7. View

13.

Angus B, Napier J, Purvis J, Ellis I, Hawkins R, CARPENTER F . Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11. J Pathol. 1986; 149(4):301-6. DOI: 10.1002/path.1711490406. View

14.

Ellis I, Robins R, Elston C, Blamey R, Ferry B, Baldwin R . A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. Histopathology. 1984; 8(3):501-16. DOI: 10.1111/j.1365-2559.1984.tb02360.x. View